Monday 25 May 2020 ,
Latest News
Eid-ul-Fitr today | Army to participate in embankment repair work: Minister | Together, we can overcome any problem: PM | Covid-19 Bangladesh: 415 recover newly; total number of recoveries 6,901. | Covid-19: Bangladesh sees highest 28 deaths in a day | Covid-19 Bangladesh: Confirmed cases now 33,610; death toll reaches 480 | Another policeman dies from coronavirus | UK extends visas for stranded foreigners till July 31 | Eid travelling amid coronavirus outbreak is ‘suicidal': Experts | Coronavirus Hotline Numbers: 01944333222, 16263, 333; website: www.corona.gov.bd |
22 May, 2020 09:16:56 PM

Print

Hydroxychloroquine shows no coronavirus benefit: Study

It increases death risk
Independent Online/ AFP
Hydroxychloroquine shows no coronavirus benefit: Study
Both drugs are associated with several potentially serious side effects

A study of nearly 100,000 coronavirus patients has shown no benefit in treating them with anti-viral drugs hydroxychloroquine and chloroquine and even increased the likelihood of them dying in hospital.

Hydroxychloroquine is normally used to treat arthritis but pronouncement from public figures including US President Donald Trump -- who announced this week he is taking the drug -- has prompted governments to bulk buy the medicine.

Chloroquine is an anti-malarial. Both drugs can produce potentially serious side effects, particularly heart arrhythmia.

Authors of a study published Friday in The Lancet said they found that the two medicines had no effect on the outcome of patients hospitalised with COVID-19.

Looking at the records of 96,000 patients across hundreds of hospitals, they found that administering the drugs actually increased the risk of dying.

They compared outcomes from four groups: those treated with hydroxychloroquine alone, with chloroquine alone, and then two groups given the respective drugs in combination with antibiotics.

There was also a control group of patients not given these treatments.

At the end of the study period around nine percent of those in the control group had died.

Of those treated with hydroxychloroquine or chloroquine alone, 18 percent and 16.4 percent respectively had died.

And those given each drug in combination with antibiotics were even more likely to die: 22.8 percent with chloroquine and 23.8 percent with hydroxychloroquine.

The authors estimated that the drugs put patients at up to 45 percent higher risk of dying from COVID-19 compared with underlying health issues.

"Treatment with chloroquine or hydroxychloroquine does not benefit patients with COVID-19," said Mandeep Mehra, lead author of the study and executive director of the Brigham and Women's Hospital Center for Advanced Heart Disease in Boston.

"Instead, our findings suggest it may be associated with an increased risk of serious heart problems and increased risk of death."

Despite Trump's enthusiasm for using hydroxychloroquine for COVID-19 treatment, his own government's Food and Drug Administration warns against it.

Brazil's health minister on Wednesday recommended using chloroquine and hydroxychloroquine to treat even mild COVID-19 cases.

Britain has ordered £35 million ($42 million, 40 million euros) worth of hydroxychloroquine, despite numerous studies showing it is ineffective in treating COVID-19 and may even be more dangerous than doing nothing.

"Several countries have advocated use of chloroquine and hydroxychloroquine, either alone or in combination, as potential treatments for COVID-19," said Frank Ruschitzka, director of the Heart Center at University Hospital Zurich and co-author of the study.

"We now know from our study that the chance that these medications improve outcomes in COVID-19 is quite low."

TH

 

.

Comments

Poll
Today's Question »
State minister for power Nasrul Hamid yesterday said everyone to have access to electricity by June. Do you think the feat achievable by the timeframe?
 Yes
 No
 No Comment
Yes 47.3%
No 48.7%
No Comment 4.1%
Video

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting